SamuelAJacobsMD
Oncology • Pittsburgh, PABreast Cancer, Gastrointestinal Cancer, Hematologic Oncology
NSABP Foundation
Dr. Jacobs is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Four Allegheny Center
5th Floor
Pittsburgh, PA 15212Phone+1 412-330-4689- Is this information wrong?
Education & Training
National Institutes of Health Clinical CenterFellowship, Medical Oncology, 1974 - 1976
UPMC Medical EducationResidency, Internal Medicine, 1971 - 1973
University of Rochester School of Medicine and DentistryClass of 1971
Certifications & Licensure
PA State Medical License 1976 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
Clinical Trials
- Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma Start of enrollment: 2003 Nov 01
Publications & Presentations
PubMed
- NSABP FC-6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild-type liver metastases receiving mFOLFOX7 plus cetuximab.Lawrence D Wagman, David A Geller, Samuel A Jacobs, Nicholas J Petrelli, Carmen J Allegra, Corey Lipchik, Katherine L Pogue-Geile, Ashok Srinivasan, Ying Wang, Michael...> ;Journal of Surgical Oncology. 2022 Dec 1
- 4 citationsDefinitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-3...Charles E Geyer Jr, Hanna Bandos, Priya Rastogi, Samuel A Jacobs, André Robidoux, Louis Fehrenbacher, Patrick J Ward, Jonathan Polikoff, Adam M Brufsky, Louise Provenc...> ;Breast Cancer Research and Treatment. 2022 Jun 1
- 1 citationsCorrection to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer...Charles E Geyer Jr, Hanna Bandos, Priya Rastogi, Samuel A Jacobs, André Robidoux, Louis Fehrenbacher, Patrick J Ward, Jonathan Polikoff, Adam M Brufsky, Louise Provenc...> ;Breast Cancer Research and Treatment. 2022 Jun 1
- Join now to see all
Press Mentions
Generex Announces Collaboration with Merck to Evaluate KEYTRUDA® (Pembrolizumab) in Combination with AE37 in Patients with Triple-Negative Breast CancerJuly 31st, 2017
Grant Support
- Core--Clinical Research Services Clinical Trials OfficeNational Cancer Institute2005–2008
- Core--Protocol Review And Monitoring SystemNational Cancer Institute2004–2008
- Cancer Center Model For Early Phase Clinical TrialsNational Cancer Institute2003–2005
- Clinical Research Services Clinical Trials OfficeNational Cancer Institute2004
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
